{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T23:02:37Z","timestamp":1793660557380,"version":"4.5.1"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2023,4]]},"DOI":"10.1016\/j.bcp.2023.115470","type":"journal-article","created":{"date-parts":[[2023,3,2]],"date-time":"2023-03-02T16:23:38Z","timestamp":1677774218000},"page":"115470","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["A precisely humanized FCRN transgenic mouse for preclinical pharmacokinetics studies"],"prefix":"10.1016","volume":"210","author":[{"given":"Christopher M.","family":"Conner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Don","family":"van Fossan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen","family":"Read","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dale O.","family":"Cowley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar","family":"Alvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon Xiang-Ru","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Webb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt","family":"Jarnagin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bcp.2023.115470_b0005","doi-asserted-by":"crossref","first-page":"2014296","DOI":"10.1080\/19420862.2021.2014296","article-title":"Antibodies to watch in 2022","volume":"14","author":"Kaplon","year":"2022","journal-title":"MAbs."},{"issue":"9","key":"10.1016\/j.bcp.2023.115470_b0010","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1002\/psp4.12224","article-title":"Pharmacokinetics of Monoclonal Antibodies","volume":"6","author":"Ryman","year":"2017","journal-title":"CPT Pharmacometrics Syst Pharmacol."},{"issue":"11","key":"10.1016\/j.bcp.2023.115470_b0015","doi-asserted-by":"crossref","first-page":"6076","DOI":"10.4049\/jimmunol.151.11.6076","article-title":"Mouse MHC class I-like Fc receptor encoded outside the MHC","volume":"151","author":"Ahouse","year":"1993","journal-title":"J Immunol."},{"issue":"3","key":"10.1016\/j.bcp.2023.115470_b0020","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1084\/jem.20021829","article-title":"The major histocompatibility complex-related Fc receptor for IgG (FcRn) binds albumin and prolongs its lifespan","volume":"197","author":"Chaudhury","year":"2003","journal-title":"J Exp Med."},{"issue":"7","key":"10.1016\/j.bcp.2023.115470_b0025","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.4049\/jimmunol.170.7.3528","article-title":"The MHC class I-like IgG receptor controls perinatal IgG transport, IgG homeostasis, and fate of IgG-Fc-coupled drugs","volume":"170","author":"Roopenian","year":"2003","journal-title":"J Immunol."},{"issue":"6203","key":"10.1016\/j.bcp.2023.115470_b0030","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/337184a0","article-title":"An Fc receptor structurally related to MHC class I antigens","volume":"337","author":"Simister","year":"1989","journal-title":"Nature."},{"issue":"12","key":"10.1016\/j.bcp.2023.115470_b0035","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1093\/intimm\/13.12.1551","article-title":"Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies","volume":"13","author":"Ober","year":"2001","journal-title":"Int Immunol."},{"issue":"1","key":"10.1016\/j.bcp.2023.115470_b0040","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ymeth.2013.07.005","article-title":"Humanized FcRn mouse models for evaluating pharmacokinetics of human IgG antibodies","volume":"65","author":"Proetzel","year":"2014","journal-title":"Methods."},{"key":"10.1016\/j.bcp.2023.115470_b0045","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/978-1-60761-058-8_6","article-title":"Human FcRn transgenic mice for pharmacokinetic evaluation of therapeutic antibodies","volume":"602","author":"Roopenian","year":"2010","journal-title":"Methods Mol Biol."},{"issue":"6","key":"10.1016\/j.bcp.2023.115470_b0050","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1369\/0022155417705095","article-title":"Distribution of FcRn Across Species and Tissues","volume":"65","author":"Latvala","year":"2017","journal-title":"J Histochem Cytochem."},{"issue":"6","key":"10.1016\/j.bcp.2023.115470_b0055","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1080\/19420862.2016.1193660","article-title":"Utility of a human FcRn transgenic mouse model in drug discovery for early assessment and prediction of human pharmacokinetics of monoclonal antibodies","volume":"8","author":"Avery","year":"2016","journal-title":"MAbs."},{"issue":"3","key":"10.1016\/j.bcp.2023.115470_b0060","doi-asserted-by":"crossref","first-page":"397","DOI":"10.4161\/mabs.23836","article-title":"Correlations between pharmacokinetics of IgG antibodies in primates vs. FcRn-transgenic mice reveal a rodent model with predictive capabilities","volume":"5","author":"Tam","year":"2013","journal-title":"mAbs."},{"issue":"1","key":"10.1016\/j.bcp.2023.115470_b0065","doi-asserted-by":"crossref","first-page":"1829337","DOI":"10.1080\/19420862.2020.1829337","article-title":"Pharmacokinetics of novel Fc-engineered monoclonal and multispecific antibodies in cynomolgus monkeys and humanized FcRn transgenic mouse models","volume":"12","author":"Valente","year":"2020","journal-title":"MAbs."},{"issue":"5","key":"10.1016\/j.bcp.2023.115470_b0070","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1038\/nprot.2007.145","article-title":"Pronuclear injection for the production of transgenic mice","volume":"2","author":"Ittner","year":"2007","journal-title":"Nat Protoc."},{"key":"10.1016\/j.bcp.2023.115470_b0075","doi-asserted-by":"crossref","unstructured":"Lai C, Alvarez O, Read K, van Fossan D, Conner CM, Xu S, et al. ROBUST AND EFFICIENT ACTIVE GENETICS GENE CONVERSION IN THE RAT AND MOUSE. bioRxiv. 2022:2022.08.30.505951.","DOI":"10.1101\/2022.08.30.505951"},{"issue":"8","key":"10.1016\/j.bcp.2023.115470_b0080","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1038\/nbt.2661","article-title":"Heritable gene targeting in the mouse and rat using a CRISPR-Cas system","volume":"31","author":"Li","year":"2013","journal-title":"Nat Biotechnol."},{"issue":"4","key":"10.1016\/j.bcp.2023.115470_b0085","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.cell.2013.04.025","article-title":"One-step generation of mice carrying mutations in multiple genes by CRISPR\/Cas-mediated genome engineering","volume":"153","author":"Wang","year":"2013","journal-title":"Cell."},{"issue":"6","key":"10.1016\/j.bcp.2023.115470_b0090","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s10529-016-2064-9","article-title":"Improved delivery of Cas9 protein\/gRNA complexes using lipofectamine CRISPRMAX","volume":"38","author":"Yu","year":"2016","journal-title":"Biotechnol Lett."},{"issue":"2","key":"10.1016\/j.bcp.2023.115470_b0095","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/ng0295-177","article-title":"Detection of mutations by cleavage of DNA heteroduplexes with bacteriophage resolvases","volume":"9","author":"Mashal","year":"1995","journal-title":"Nat Genet."},{"issue":"1","key":"10.1016\/j.bcp.2023.115470_b0100","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1038\/s41598-018-19441-8","article-title":"A Survey of Validation Strategies for CRISPR-Cas9 Editing","volume":"8","author":"Sentmanat","year":"2018","journal-title":"Sci Rep."},{"issue":"1","key":"10.1016\/j.bcp.2023.115470_b0105","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1089\/crispr.2021.0113","article-title":"Inference of CRISPR Edits from Sanger Trace Data","volume":"5","author":"Conant","year":"2022","journal-title":"CRISPR J."},{"issue":"8","key":"10.1016\/j.bcp.2023.115470_b0110","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1080\/19420862.2016.1229721","article-title":"Utility of immunodeficient mouse models for characterizing the preclinical pharmacokinetics of immunogenic antibody therapeutics","volume":"8","author":"Myzithras","year":"2016","journal-title":"MAbs."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295223000618?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295223000618?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T18:19:57Z","timestamp":1736360397000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295223000618"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4]]},"references-count":22,"alternative-id":["S0006295223000618"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2023.115470","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A precisely humanized FCRN transgenic mouse for preclinical pharmacokinetics studies","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2023.115470","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115470"}}